Oral etoposide combined with realgar natural indigo tablets and all-trans retinoic acid in the treatment of high-risk acute promyelocytic leukemia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053926

Enrollment

Unknown

Registered

2021-12-02

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk acute promyelocytic leukemia

Interventions

Experimental group:Oral etoposide combined with realgar natural indigo tablets and all-trans retinoic acid

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Newly treated high-risk APL (WHO 2016 diagnostic classification); 2. Aged 18 to 70 years (including 18 and 70); 3. Renal function: creatinine <= 3 times the upper limit of normal; 4. Liver function: ALT and AST <= 2.5 times the upper limit of normal, bilirubin <= 2 times the upper limit of normal.

Exclusion criteria

Exclusion criteria: 1. Accompanied by cerebral hemorrhage; 2. Pregnancy; 3. Suffering from mental illness or other conditions that cannot be carried out according to the plan; 4. Unable to take oral medicines; 5. Uncontrolled active infection; 6. Organ failure; 7. Allergy to etoposide.

Design outcomes

Primary

Measure	Time frame
remission rate;death rate;	—

Secondary

Measure	Time frame
cumulative recurrence rate;Event free survival rate;Overall survival rate;safety;	—

Countries

China

Contacts

Public ContactJiang Hao

Peking University People's Hospital

2516735116@qq.com+86 13601164350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026